Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Science
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Find Cricket Statistics
Hindi
More
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Science
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / Coronavirus: Serum Institute ordered to halt recruitment for vaccine trial
  • India

    Coronavirus: Serum Institute ordered to halt recruitment for vaccine trial

    Shalini Ojha
    Written by
    Shalini Ojha
    Twitter
    Last updated on Sep 12, 2020, 09:28 am
    Coronavirus: Serum Institute ordered to halt recruitment for vaccine trial
  • The Drugs Controller General of India (DCGI) has ordered the Serum Institute of India (SII) to pause the recruitment of volunteers for Phase 2 and Phase 3 trials of the coronavirus vaccine, being developed by the University of Oxford and UK-pharma giant AstraZeneca.

    This development comes after Pune-based SII paused testing , buoyed by AstraZeneca's decision to suspend trial as a volunteer fell ill.

  • In this article
    SII asked to increase monitoring of those who got vaccinated AstraZeneca paused trial after woman fell ill; SII continued process After stern notice, SII also paused trial SII's reply to DCGI led to the latest development Reportedly, phase 3 was set to start soon Shouldn't be discouraged, said WHO on AstraZeneca pause
  • Order

    SII asked to increase monitoring of those who got vaccinated

    SII asked to increase monitoring of those who got vaccinated
  • According to PTI, Director Dr. VG Somani also told SII to amp up the safety monitoring of those who got vaccinated. The firm was also directed to submit the report.

    Moreover, SII was told it has to get clearance from the Data and Safety Monitoring Board (DSMB), both in UK and in India, before getting a green signal from the regulator for resuming recruitment.

  • Looking back

    AstraZeneca paused trial after woman fell ill; SII continued process

  • This week, AstraZeneca informed it was pausing trial globally after a volunteer developed an "adverse reaction" to the vaccine, dubbed as the frontrunner in the global race.

    The woman, CEO Pascal Soriot, said had "neurological symptoms consistent with a rare but serious spinal inflammatory disorder." AstraZeneca assured it wouldn't compromise on safety.

    Despite a setback around the world, SII went ahead with the process.

  • Series of events

    After stern notice, SII also paused trial

  • SII's decision to continue with the trial earned it a notice from DCGI.

    In the show-cause notice, the regulator asked the firm why it hadn't informed about AstraZeneca's pause, why it was continuing the trial, and also wondered why the permission shouldn't be revoked.

    Hours after the stern communication, SII said it has halted the trial and will resume after AstraZeneca does the same.

  • Reply

    SII's reply to DCGI led to the latest development

  • Notably, in its reply, SII noted that India's Data Safety Monitoring Board (DSMB) didn't flag any safety concerns after "the first dose and seven days post-vaccination safety data."

    DSMB, however, "recommended pausing further enrollment into the study until ongoing investigations of the issues reported in the UK study is completed," SII added.

    This reply formed the basis of DCGI's latest order pertaining to recruitment.

  • Trial

    Reportedly, phase 3 was set to start soon

    Reportedly, phase 3 was set to start soon
  • As part of its plan to conduct the trial in India, SII had zeroed in one 17 sites.

    Phase 2 of the human trial began in Pune on August 27, but its unclear how many volunteers were administered the vaccine.

    The phase 3 trial was supposed to start next week and some 1,600 volunteers were selected, a report in NDTV said.

  • Statement

    Shouldn't be discouraged, said WHO on AstraZeneca pause

    Shouldn't be discouraged, said WHO on AstraZeneca pause
  • The AstraZeneca pause, naturally, caused displeasure to a battered globe waiting for a respite from COVID-19.

    However, WHO's Chief Scientist Soumya Swaminathan said there's not much to be discouraged about.

    "I think this is good... perhaps a wake-up call or lesson for everyone to recognize that there are ups and downs in research, there are ups and downs in clinical development," Swaminathan said.

  • Vaccine
  • NDTV
  • PTI
  • University of Oxford
  • Soumya Swaminathan
  •  
Latest News
  • NewsBytes Briefing: Investigation uncovers Facebook's pro ISIS move, and more
    NewsBytes Briefing: Investigation uncovers Facebook's pro ISIS move, and more
    Science
  • PUBG: New State announced for iOS, Android; Unavailable in India
    PUBG: New State announced for iOS, Android; Unavailable in India
    Science
  • Indian versions of 'Suits', 'House', 'Monk', 'SNL' are being planned
    Indian versions of 'Suits', 'House', 'Monk', 'SNL' are being planned
    Entertainment
  • Google integrates lightweight HTML5 games into Chrome browser on Android
    Google integrates lightweight HTML5 games into Chrome browser on Android
    Science
  • Sony announces next-generation PSVR headset for the PlayStation 5
    Sony announces next-generation PSVR headset for the PlayStation 5
    Science
Related Timelines
  • SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
    SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
    India
  • UK's approval to Oxford-AstraZeneca vaccine paves way for India
    UK's approval to Oxford-AstraZeneca vaccine paves way for India
    India
  • SII says Covishield 'safe' after trial participant sends legal notice
    SII says Covishield 'safe' after trial participant sends legal notice
    Science
  • SII to sue vaccine trial participant for Rs. 100 crore
    SII to sue vaccine trial participant for Rs. 100 crore
    Science
Trending Topics
ISRO Vaccine Farmers Protest
Next News Article
Share
Cancel

Want to share it with your friends too?

Facebook Whatsapp Twitter Linkedin
Copied

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Science News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Bharti Airtel Mukesh Ambani Indian Premier League Samsung Virat Kohli Rohit Sharma
Cricket News Narendra Modi Facebook YouTube Hollywood News WhatsApp Bollywood News ISRO Rahul Gandhi Yoga
Honda Batman Football News BMW Vaccine Reliance Jio OPPO Amazon Food News, Healthy Recipes Royal Challengers Bangalore
Toyota Fashion Tips Farmers Protest Mercedes Isha Ambani India Vs England Cricket OnePlus Mobiles Android TV Smart TV Marvel Comics
Avengers Neha Kakkar Premier League Big Bang Theory
About Us Privacy Policy Terms & Conditions Contact Us News Reviews News Archive Topics Archive Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2021